Daily Stock Market Summary ( Tuesday, September 29, 2026): Stocks Finish Lower As Yields Stay Elevated -( $AMZN $CCL $DOCS $EPRX $F $FICO $IOVA $META $MODD $SER $SHOP $TGT $WMT $YSG )

U.S. stocks closed modestly lower Tuesday as investors weighed still-elevated Treasury yields, a weaker consumer-confidence reading and an ongoing rotation toward selective company-specific opportunities. The Dow Jones Industrial Average fell 131.59 points, or 0.26%, to 51,349.92; the S&P 500 slipped 0.17% to 7,697.91; the Nasdaq Composite declined 0.09% to 26,797.54; and the Russell 2000 lost 0.35% to 2,807.92.

Market Close

Macroeconomic Commentary

The U.S. market’s late-session posture reflected a familiar macro tension: bond yields remain high enough to constrain equity valuations, yet investors are still finding reasons to maintain exposure to companies with differentiated growth, pricing power or major operational catalysts. The 10-year U.S. Treasury yield finished at 5.26%, rising 0.01 percentage point on the day. Yields at these levels matter because they increase the return available from lower-risk fixed-income securities, raise borrowing costs across the economy and apply greater valuation pressure to long-duration growth stocks. That backdrop helps explain why the Nasdaq’s 0.09% decline was comparatively limited but still notable despite a steady flow of AI-related product announcements and corporate developments. A decline in consumer confidence added another layer of caution. The Conference Board’s Consumer Confidence Index fell to 81.9 in September from 88.6 in August, below economists’ expectations. The report suggested that consumers are becoming more concerned about business conditions, employment prospects and household financial conditions—a potentially important development as retailers prepare for the holiday-shopping period. At the same time, the sharp 4.03% pullback in November WTI crude oil to $88.87 per barrel provided an offset to recent inflation and geopolitical concerns. Lower energy prices can relieve pressure on consumer budgets and inflation expectations, though traders will continue monitoring supply risk, regional instability and the durability of the move lower. Gold advanced 1.11% to $4,214.70 per ounce, illustrating continued demand for portfolio hedges amid uncertainty around rates, inflation and geopolitical conditions. Bitcoin edged 0.16% higher to $83,631.80, while the VIX eased 0.19% to 16.04, signaling that the equity-market decline remained orderly rather than panic-driven.

Corporate and Sector News

AI shifts toward workplace execution

OpenAI introduced Dots, an AI-agent platform designed to execute longer-running tasks across workplace software, including Slack-based workflows and scheduling functions. The product launch highlights intensifying competition in agentic AI, including against Meta Platforms, Inc. (NASDAQ: META) and its Muse product. Rather than simply generating content or answering questions, the emerging focus is on AI systems that can take action across interconnected business tools. For many, the commercial issue is increasingly whether companies can translate generative AI interest into recurring software revenue, lower operating costs and new digital-commerce channels. That dynamic could benefit infrastructure suppliers, cloud providers, cybersecurity companies and platforms that control customer and transaction data. Shopify Inc. (NYSE: SHOP) was also in focus after Morgan Stanley identified the e-commerce company as a potential agentic-shopping beneficiary. As consumers increasingly use AI interfaces for product comparisons, recommendations and purchasing decisions, Shopify’s merchant ecosystem could become more valuable if it remains well integrated with AI-driven discovery and checkout experiences. Princess Cruises, a brand owned by Carnival Corp. & plc (NYSE: CCL), announced a ChatGPT-native cruise-planning application. The tool is designed to help travelers search itineraries, evaluate pricing and narrow travel choices in a conversational format. The launch provides another example of a consumer-facing company seeking to establish visibility and transaction utility directly within large-language-model environments.

Retail prices and holiday demand

Target Corp. (NYSE: TGT) said it is reducing prices on nearly 2,000 home, apparel and accessory products ahead of the holiday season. The retailer also cited more than 10,000 price cuts made during the prior year, as it competes for value-conscious consumers with Walmart Inc. (NYSE: WMT) and Amazon.com, Inc. (NASDAQ: AMZN). Target’s promotion strategy comes as consumer sentiment weakens and shoppers remain focused on value. While lower prices may support traffic and unit demand, the market will watch whether the company can protect gross margins while using promotions to improve holiday-season sales momentum. Target’s stock closed down 1.28%, Walmart fell 1.78%, and Amazon rose 0.21%.

Ford sees intensifying China challenge

Ford Motor Co. (NYSE: F) CEO Jim Farley said Europe may have waited too long to prevent Chinese automakers from establishing a major competitive presence, while arguing that the United States still has an opportunity to shape its response. Chinese vehicle manufacturers have gained market share across global markets, increasing the competitive pressure on legacy automakers in EVs, batteries, technology and cost-efficient production. Ford’s response reflects the broader strategic challenge for global automakers: compete directly against Chinese brands while selectively pursuing partnerships that provide access to batteries, manufacturing capabilities or technology. Ford and Geely Automobile Holdings Ltd. have discussed an EV-related production arrangement at a Ford-owned facility in Spain.

Iovance rallies on outlook increase

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) surged 31.48% to $14.45 after raising its full-year 2026 revenue guidance to a range of $410 million to $420 million. The revised forecast represented a $55 million increase at the midpoint from previous guidance of $350 million to $370 million, driven by demand for Amtagvi and Proleukin.. The company said its updated outlook implies nearly 60% annual revenue growth and cited a growing network of authorized treatment centers. The gain underscored continued investor interest in biotechnology companies that can demonstrate commercial traction, though the sector remains exposed to clinical, regulatory, manufacturing, reimbursement and financing risks.

What Many Are Watching

• Bond yields: The 10-year Treasury yield at 5.26% remains a key factor for equity valuations, financing conditions and sector leadership.
• Consumer health: The September confidence decline increases the importance of upcoming retail sales, labor-market and holiday-demand signals.
• Energy and inflation: WTI crude’s 4.03% drop to $88.87 offers near-term inflation relief, but the sustainability of the decline remains uncertain.
• AI commercialization: OpenAI’s Dots launch, Shopify’s agentic-commerce opportunity and Carnival’s ChatGPT integration show that practical deployment is becoming central to the AI investment narrative.
• Stock-specific catalysts: Iovance’s guidance increase and the sharp decline in Fair Isaac Corp. (NYSE: FICO) following mortgage-credit-score policy developments illustrate how company-specific events can drive outsized moves even in a relatively quiet index session.

The Sources

1. CNBC Stock Market Today: Live Updates
2. CNBC Ford CEO Jim Farley Says It Is “Too Late” for Europe to Fend Off Chinese Automakers, but Not the U.S.
3. Yahoo Finance OpenAI Debuts Dots AI Agents in Challenge to Meta’s Popular Muse Agent
4. Yahoo Finance Target Cuts Prices on Nearly 2,000 Products Ahead of Holidays
5. Yahoo Finance Iovance Biotherapeutics Raises Full-Year 2026 Revenue Guidance to $410 Million–$420 Million
6. Yahoo Finance / PR Newswire Princess Cruises Becomes First Global Cruise Line to Launch AI-Powered Cruise-Planning App for Large Language Models

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $13.44, +.07%.

AMWL announced (Sept 8) announced the Department of Veterans Affairs (VA) has declared its intent for the Company to deploy its virtual health platform within the VA enterprise and help power the modernization of the VA’s digital health infrastructure. The VA anticipates the Amwell platform will support a broad range of clinical services, enhance care coordination, and improve access for our Veterans across the VA enterprise. The Letter of Intent follows a comprehensive evaluation process by the VA, in which it determined that Amwell’s virtual health platform aligns with the Department’s strategic objectives to expand access to high-quality, secure, and reliable virtual care services for Veterans nationwide through the VA’s current electronic health record modernization efforts. Specifically, the capabilities Amwell demonstrated in scalable video consultations, interoperability, cybersecurity compliance, and support for integrated care delivery were significant factors in this determination.

Amwell® has received Frost & Sullivan’s 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms Industry. The recognition validates Amwell’s ability to address healthcare fragmentation through a unified platform that orchestrates consumer experiences, clinician workflows, care programs, and partner solutions.

The Company also reiterated recently its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $2..08, +3.48%) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

SER announced (Sept. 9) that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson’s disease and recommended that the study advance to Cohort 2. Cohort 1 evaluated the lowest dose level in the single-ascending-dose portion of the study. In addition to supporting continued dose escalation, blinded Cohort 1 observations showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide and included sustained periods of improvement in motor function in individual patients on exploratory clinical measures.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $11.69, +1.39%) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space. HPP turned in a quarter ( Aug. 5) that suggests the office malaise is not over, but it may finally be meeting resistance. Revenue came in above Wall Street’s expectations, occupancy moved higher for a fourth straight quarter, and management raised full-year guidance, a combination that does not make for a triumphant victory lap, but it does make for a more credible turnaround narrative. Learn more.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $8.31, +1.16%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (Aug. 13) positive results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity, including for the first time an analysis of the effect of EP-104GI on odynophagia (pain when swallowing). This is important because odynophagia scoring is a component of Dysphagia Symptom Questionnaire (DSQ), a commonly used patient reported outcome used in pivotal clinical trials in EoE patients.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $1.95), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, announced (September 4) that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company’s Pivot insulin delivery system is now available through the national PBM. The Company believes the engagement with this national PBM represents a significant step forward in broadening patient access to the Company’s Pivot tubeless patch pump and will further validate the Pivot pump as an accessible therapeutic option for people living with diabetes.

MODD announced (September 3) that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system’s functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades.

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026 (8:30am PT / 11:30 am ET). You may watch the event video below now if you missed it below now.

MODD announced (Aug. 3) plans to initiate the first phase of commercialization of its Pivot tubeless patch pump across five strategically selected U.S. markets beginning in October 2026. The initial rollout will include Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia, representing a foundational step in the Company’s capital efficient commercialization strategy with its mission to expand access to simplified insulin delivery solutions for all people living with diabetes.

MODD recently (July 22) announced the formation of its Pivot Innovation Council, a cross-functional group of leading clinicians and healthcare experts established to help guide the company’s clinical and commercial strategy. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.

Modular released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $3, +.67%) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $2.55, +.79%), a leading China-based beauty group, delivered the sort of quarter that can make a turnaround investor sit up straighter: reported revenue grew, its strategically important skincare operation accelerated sharply, and the company is increasingly built around clinical and premium brands rather than a pure color-cosmetics play. The results are not yet a victory lap, losses widened and third-quarter guidance is cautious, but YSG’s transformation is beginning to look less like a cosmetic touch-up and more like a genuine renovation.

YSG announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $26.52, +1.22%) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

Doximity, Inc. (NYSE: DOCS) announced (Aug. 6) results of its fiscal 2027 first quarter ended June 30, 2026. Jeff Tangney, co-founder and CEO of Doximity, “We’re proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement. In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”

Fiscal 2027 First Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended June 30, 2025.

• Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.
• Net income and non-GAAP net income: Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%. Non-GAAP net income of $55.0 million, versus $71.9 million, representing a margin of 35.1%, versus 49.2%.
• Adjusted EBITDA: Adjusted EBITDA of $74.8 million, versus $79.8 million, a decrease of 6% year-over-year, representing adjusted EBITDA margins of 47.7%, versus 54.7%.
• Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.
• Operating cash flow and free cash flow: Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million, a decrease of 34% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal second quarter ending September 30, 2026 as follows:

• Revenue between $170 million and $171 million.
• Adjusted EBITDA between $80.5 million and $81.5 million.

Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:

• Revenue between $671 million and $681 million.
• Adjusted EBITDA between $309 million and $329 million.

Sable Offshore Corp. (SOC)

Sable Offshore Corp. (NYSE: SOC, $3.40) has moved from the awkward “pre-revenue restoration project” phase into something much more recognizable to Wall Street: a company selling meaningful volumes of oil, generating operating cash flow, and building momentum into a potentially larger 2027 earnings base. The second-quarter report on Monday was not a polished victory lap—midstream bottlenecks and one-time costs made sure of that, but it offered something potentially more valuable: proof that the Santa Ynez Unit restart is translating into barrels, revenue, and operational traction. Learn more.

Nvidia (NVDA, $227.21,-.72%)

NVIDIA Corp. (NASDAQ: NVDA) seemingly has given many a two-part bullish signal: a record-sized $150 billion increase to its share-repurchase authorization and a new AI-agent safety platform aimed at making autonomous software more secure for enterprise deployment. The combination suggests a company using extraordinary financial strength not merely to reward shareholders, but to expand its influence from AI computing into the governance, security and operating layer of the AI economy. The timing is notable. Markets are beginning the week with a cautiously constructive tone, even as investors brace for jobs, inflation and manufacturing data that could reset the outlook for interest rates. In that environment, NVIDIA is making a familiar but potent argument: its AI franchise is generating enough cash to finance innovation, deepen its ecosystem and return meaningful capital to shareholders, all at once. That is not an everyday corporate trick. It is closer to juggling bowling balls while also building the bowling alley.

The Sources

1. CNBC Stock Market Today: Live Updates
2. CNBC Ford CEO Jim Farley Says It Is “Too Late” for Europe to Fend Off Chinese Automakers, but Not the U.S.
3. Yahoo Finance OpenAI Debuts Dots AI Agents in Challenge to Meta’s Popular Muse Agent
4. Yahoo Finance Target Cuts Prices on Nearly 2,000 Products Ahead of Holidays
5. Yahoo Finance Iovance Biotherapeutics Raises Full-Year 2026 Revenue Guidance to $410 Million–$420 Million
6. Yahoo Finance / PR Newswire Princess Cruises Becomes First Global Cruise Line to Launch AI-Powered Cruise-Planning App for Large Language Models